Hyperbaric Oxygen Therapy and Angiogenesis in Diabetic Patients With Foot Ulcers

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by Assaf-Harofeh Medical Center.
Recruitment status was  Recruiting
Information provided by:
Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:
First received: May 16, 2007
Last updated: May 17, 2007
Last verified: May 2007

Diabetic foot ulcers are a major cause of morbidity and mortality, accounting for approximately two-thirds of all non-traumatic amputations performed in the United States. The cost of foot ulcers in diabetic patients averages almost $28,000 for the two years after diagnosis of the ulcer. Hyperbaric oxygen (HBO) serves as primary or adjunctive therapy for a diverse range of medical conditions. HBO also has been used as an adjunct to antibiotics, debridement, and revascularization in the therapy of chronic, nonhealing wounds associated with diabetes or non-diabetic vascular insufficiency.

The aim of the study is to assess whether hyperoxia induced angiogenesis in diabetic patients with foot ulcers.

Diabetic Foot Ulcers
Hyperbaric Therapy

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18 years or older, with type II diabetes suffering from foot ulcers admitted to the Institute of Hyperbaric Medicine and Wound Care Clinic at Assaf Harofeh Medical Center (Israel)

Exclusion Criteria:

  • Patients having chest pathology incompatible with pressure changes, inner ear disease, or suffering from claustrophobia, will be excluded from the study. Patients with significant macrovascular disease, defined as obstruction of more than 50% in the femoral or the popliteal arteries, will also be excluded from the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00475202

Contact: Albert Rabinovitz, MD +972-546-396503 alik.r75@mail.ru

Institute of Hyperbaric Medicine and Wound Care Clinic at Assaf Harofeh Medical Center Recruiting
Zerifin, Israel, 70300
Contact: Albert Rabinovitz, MD    +972-546-39503    alik.r75@mail.ru   
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Principal Investigator: Albert Rabinovitz, MD Assaf-Harofeh Medical Center
Study Chair: Efrati Shai, MD Assaf-Harofeh Medical Center
  More Information

ClinicalTrials.gov Identifier: NCT00475202     History of Changes
Other Study ID Numbers: 6106 
Study First Received: May 16, 2007
Last Updated: May 17, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Diabetic Angiopathies
Diabetic Foot
Foot Ulcer
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Neuropathies
Endocrine System Diseases
Foot Diseases
Leg Ulcer
Skin Diseases
Skin Ulcer
Vascular Diseases

ClinicalTrials.gov processed this record on May 26, 2016